<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568347</url>
  </required_header>
  <id_info>
    <org_study_id>20061697A</org_study_id>
    <nct_id>NCT00568347</nct_id>
    <nct_alias>NCT00569348</nct_alias>
  </id_info>
  <brief_title>Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange</brief_title>
  <official_title>Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthur F Gelb MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelb, Arthur F., M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of inhaled corticosteroids to suppress nitric oxide gas exchange in
      stable patients with moderate-to-severe COPD who are current non-smokers and not on oral
      corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stable, non-smoking COPD patients not on oral corticosteroids will be randomized in single
      blinded study to evaluate nitric oxide gas exchange at baseline, and subsequent effects of
      fluticasone 100mcg/salmeterol 50mcg bid, and fluticasone 250mcg/salmeterol 50mcg bid. Primary
      end points will include measurements of nitric oxide at varying expiratory flow rates to
      calculate bronchial, and small airway/alveolar nitric oxide. Secondary end points will
      evaluate lung function. Exhaled nitric oxide production presumably reflects endogenous
      inflammation. Normal healthy, non-smoking controls will be used for comparison, with exhaled
      nitric oxide measured before and after 3 weeks of low dose inhlaed corticosteroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>total exhaled, bronchial, and small airway/alveolar nitric oxide</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung function</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>long acting bronchodilator</arm_group_label>
    <description>salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bronchodilator/ inhaled corticosteroid</arm_group_label>
    <description>fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>Fluticasone 100mcg/salmeterol 50mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone 100mcg/ salmeterol 50mcg</intervention_name>
    <description>inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Advair 100/50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone 250/salmeterol 50</intervention_name>
    <description>inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide</description>
    <arm_group_label>bronchodilator/ inhaled corticosteroid</arm_group_label>
    <other_name>Advair 250/50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <description>salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Serevent 50mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>salmeterol 50mcg bid X 3months</description>
    <arm_group_label>long acting bronchodilator</arm_group_label>
    <other_name>serevent 50 mcg disk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol and fluticasone propionate</intervention_name>
    <description>salmeterol 50mcg/fluticasone 250mcg by DPI bid</description>
    <arm_group_label>bronchodilator/ inhaled corticosteroid</arm_group_label>
    <other_name>Advair 250/50</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of copd

          -  Current non-smoker

          -  Not on oral corticosteroids

          -  Must be able to use Advair discus or salmeterol discus

        Exclusion Criteria:

          -  Pregnancy

          -  Current smoker

          -  On corticosteroids

          -  Clinically unstable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur F Gelb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur F Gelb Medical Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthur F Gelb MD</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gelb AF, Flynn Taylor C, Shinar C. Nitric Oxide gas exchange in COPD. Am J Respir Crit Care Med 2007; 174: A630.</citation>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Gelb, Arthur F., M.D.</investigator_affiliation>
    <investigator_full_name>Arthur F Gelb MD</investigator_full_name>
    <investigator_title>Arthur F Gelb MD</investigator_title>
  </responsible_party>
  <keyword>chronic airflow obstruction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

